Vor Biopharma screens as a high-asymmetry, momentum-recovering speculative biotech (4.0 asymmetry ratio, 60% modeled upside) but carries a quality score far below the engine's floor, an EXTREME insider-selling gate failure, and a 69% drawdown that keep the setup firmly in binary-catalyst territory.
Thesis pillars
- Quality Below Floor Cash Burning→Stable
- High Asymmetry Analyst Upside→Stable
- Extreme Insider Selling Gate Failure→Stable
- +2 more pillars — see the Why tab for full reasoning
Vor Biopharma Inc. (VOR) Stock Analysis
Recovery setup · Inst Constrain edge
Healthcare · Biotechnology
Sell if holding. Engine safety override at $20.31: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.2/10 and A.R:R 4.2:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 13%; Below-average business quality.
Vor Bio is a clinical-stage biopharmaceutical company developing telitacicept, a fusion-protein therapy licensed from RemeGen in June 2025 outside Greater China, running global Phase 3 trials in myasthenia gravis and Sjogren's disease. Pre-revenue, Vor Bio paid RemeGen a $125... Read more
Sell if holding. Engine safety override at $20.31: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.2/10 and A.R:R 4.2:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 13%; Below-average business quality. Chart setup: Death cross but MACD improving, RSI 82. Score 5.2/10, moderate confidence.
Passes 7/9 gates (positive momentum, favorable risk/reward ratio, no SEC red flags, news events none recent, earnings proximity 38d clear, semi cycle peak clear, materials cycle peak clear). Fails on clean insider activity. Suitability: speculative.
About Vor Biopharma Inc.
About Vor Biopharma Inc.
Vor Bio's lead and only clinical asset, telitacicept, is already approved in China for systemic lupus erythematosus, rheumatoid arthritis, and generalized myasthenia gravis (gMG), and the FDA granted the therapy Fast Track Designation for Sjogren's disease (SjD) in March 2024 after clearing the IND in January 2024. The company is now running global Phase 3 trials in gMG and SjD across the United States, Europe, South America, and Asia, with SjD's first patient dosed in March 2026.
Vor Bio generates no product revenue; it in-licensed telitacicept from RemeGen in June 2025 for all territories outside Greater China, paying a $125 million upfront fee -- $45 million in cash plus an $80 million warrant -- and owes RemeGen up to $330 million in regulatory milestones, up to $3.775 billion in sales milestones, and tiered royalties ranging from high single-digit to mid-teen percentages of net sales. Vor Bio is responsible for development, regulatory, and commercialization costs in its licensed territory, while RemeGen retains rights and continues its own trials in Greater China. The company relies on third-party contract manufacturers for clinical supply of telitacicept and does not yet have long-term manufacturing agreements in place. In the crowded autoimmune-disease field, Vor Bio competes against fusion-protein and biologic developers including Amgen and argenx, among others already marketed or in development.
Show full overview
Vor Bio's valuation rests on a single asset: the 10-K states plainly that the company is substantially dependent on telitacicept's success, with no other clinical or commercial program to fall back on. That dependence is compounded by a data-control gap: Vor Bio's Phase 3 program partly relies on trial data RemeGen generates and controls in China, and Vor Bio has no authority over those trials or their reporting to Chinese regulators, leaving U.S. and European outcomes partly dependent on a partner's execution. The company's September 2025 1-for-20 reverse stock split, disclosed alongside $455.2 million in cash meant to fund operations into early 2029, underscores the execution risk already priced in ahead of the SjD and gMG Phase 3 readouts.
See also: Healthcare · Biotechnology
From Vor Biopharma Inc.'s most recent 10-K filing, extracted July 6, 2026.
Recent developments
updated 2026-07-08Recent Developments — Vor Biopharma Inc.
Latest news
- NEWS Rivian Automotive, Tenax Therapeutics, Robinhood And Other Big Stocks Moving Higher On Thursday — benzinga Jul 2, 2026 neutral
Generated 2026-07-08T21:03:53Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Concentration Risks(10-K Item 1A)
- HIGHpipelinetelitacicept10-K Item 1A: 'We are substantially dependent on the success of our lead product candidate, telitacicept.'
- HIGHcounterpartyRemeGen10-K Item 1A: 'We have no control over the conduct and timing of, ... the trials that RemeGen is conducting for telitacicept.'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers·1 ceiling hit
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Volatile — 7.3% daily ATR makes tight stops impractical. Position-size conservatively.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $20.31: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.2/10 and A.R:R 4.2:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 13%; Below-average business quality. Chart setup: Death cross but MACD improving, RSI 82. Prior stop was $18.89. Score 5.2/10, moderate confidence.
Take-profit target: $32.95 (+62.2% upside). Prior stop was $18.89. Stop-loss: $18.89.
Concentration risk — Pipeline: telitacicept; Concentration risk — Counterparty: RemeGen; Quality below floor (1.5 < 4.0).
Vor Biopharma Inc. trades at a P/E of N/A (forward -5.4). TrendMatrix value score: 9.0/10. Verdict: Sell.
13 analysts cover VOR with a consensus score of 4.2/5. Average price target: $38.
What does Vor Biopharma Inc. do?Vor Bio is a clinical-stage biopharmaceutical company developing telitacicept, a fusion-protein therapy licensed from...
Vor Bio is a clinical-stage biopharmaceutical company developing telitacicept, a fusion-protein therapy licensed from RemeGen in June 2025 outside Greater China, running global Phase 3 trials in myasthenia gravis and Sjogren's disease. Pre-revenue, Vor Bio paid RemeGen a $125 million upfront fee and owes milestone and royalty payments on future sales. Telitacicept is approved in China for lupus, rheumatoid arthritis, and myasthenia gravis.